tiprankstipranks
Advertisement
Advertisement
Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
PremiumCompany AnnouncementsAlterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
9d ago
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
Premium
The Fly
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
12d ago
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
Premium
Company Announcements
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
12d ago
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
PremiumCompany AnnouncementsAlterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
1M ago
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
Premium
The Fly
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
2M ago
Alterity Therapeutics presents new data analyses from ATH434 trial
Premium
The Fly
Alterity Therapeutics presents new data analyses from ATH434 trial
2M ago
Alterity Therapeutics recognizes MSA Awareness Month
PremiumThe FlyAlterity Therapeutics recognizes MSA Awareness Month
4M ago
Alterity Therapeutics provides corporate update
Premium
The Fly
Alterity Therapeutics provides corporate update
5M ago
Alterity Therapeutics highlights key 2026 objectives
Premium
The Fly
Alterity Therapeutics highlights key 2026 objectives
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100